Regulatory/Legislative News

The TrueTear intranasal tear neurostimulator has been granted marketing authorization from the FDA, according to an Allergan press release.

The FDA has accepted a new drug application for intravitreal sirolimus for the treatment of non-infectious uveitis of the posterior segment, Santen announced in a press release.

Welcome to another edition of CEDARS/ASPENS Debates. CEDARS/ASPENS is a joint society of cornea, cataract and refractive surgery specialists, here to discuss some of the latest hot topics in ophthalmology.

The FDA has approved Lucentis for monthly treatment of all forms of diabetic retinopathy, according to a press release from Genentech/Roche.

It is my pleasure to announce exciting changes to our editorial board. In an effort to continually evolve in covering ophthalmology, I met recently with the editorial team of OSN to make some significant changes to the board.

Welcome to another edition of CEDARS/ASPENS Debates. CEDARS/ASPENS is a joint society of cornea, cataract and refractive surgery specialists, here to discuss some of the latest hot topics in ophthalmology.

AU-011, an investigational, first-in-class targeted therapy for ocular melanoma treatment, was granted fast track designation by the FDA, according to a press release from Aura Biosciences.

The first quarter of 2017 saw new developments at the FDA for many ophthalmic drug candidates or technological developments.

COLLINGSWOOD, NJ — New Jersey residents and a panel of health care professionals and advocates voiced their concerns about the fate of the Affordable Care Act on Thursday at a community event organized by Congressman Donald Norcross (D).

ORLANDO, Fla. — In a video perspective from the American Academy of Dermatology Annual Meeting, Michael Sherling, MD, MBA, discusses the components of the Merit-based Incentive Payment System, known as MIPS, and how a physician can perform well with it.